In 618 MASLD patients following 48 weeks of guideline-based lifestyle management, metabolic-cluster subtypes outperformed hepatic-trait and biochemical-pattern systems for temporal stability (62.8% vs 56.6% vs 53.4%). The high lipoprotein(a) cluster showed blunted liver fat reduction on MRI-PDFF (OR 0.35), the age-related cluster had weaker ALT response (OR 0.33), and the mild obesity/dyslipidemia cluster achieved better fibrosis-stage improvement by stiffness measurement.
Fatty liver is not one disease, and this work adds to evidence that identical diet-and-exercise prescriptions produce uneven results depending on underlying metabolic physiology. The lipoprotein(a) finding is the most intriguing: Lp(a) is largely genetically fixed and diet-resistant, so a subgroup whose liver fat resists lifestyle change fits a plausible mechanism and may flag patients who need earlier pharmacologic or cardiovascular risk attention. The age-related cluster's poor ALT response is a reminder that enzyme normalization is a crude marker in older adults.
Caveats matter. This is a single-centre, observational cohort with no control arm, so subtype effects cannot be separated from adherence, baseline severity, or regression to the mean. Fibrosis response relied on liver stiffness rather than biopsy, and 62.8% cluster stability means over a third of patients shifted category, which undermines clinical use of fixed labels. Cluster definitions also depend on measurements, such as Lp(a), not routinely ordered. Editorially, this is incremental and hypothesis-generating: a reason to test subtype-matched therapy prospectively, not yet a basis for changing how patients are managed. Anyone with MASLD should still pursue weight loss and exercise, and ask their clinician about Lp(a) and cardiovascular risk.